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ABSTRACT 
 
Type 2 diabetes and obesity are multifactorial diseases involving interactions between 
genetic and environmental factors. A common feature shared between these two 
diseases is skeletal muscle insulin resistance. Insulin resistance refers to a state when 
the normal biological effect is not achieved by a normal amount of insulin. 
Complicated genetics alone is unlikely to explain the diversity of phenotypes in the 
general population. Epigenetics provides a mechanism which may explain the etiology 
of Type 2 diabetes and obesity, as well as other human diseases. 
DNA methylation is an epigenetic modification that plays a key role in various 
biological processes including imprinting, mammalian development and maintaining 
genomic stability. DNA methylation is believed to be modulated by environmental and 
nutritional factors, essentially functioning as a molecular switch to turn genes on or 
off. The research on the role of DNA methylation in metabolic diseases is still in its 
infancy. This thesis aims at elucidating the role of DNA methylation in regulating 
expression of genes involved in controlling mitochondrial function and insulin 
sensitivity. Emphasis has been placed on the role of methylation in a non-CpG context. 
DNA methylation in a CpG context is considered to be the predominant DNA 
methylation pattern in mammals. The existence of non-CpG methylation in mammals 
is still under discussion. In Paper I, we provide evidence that high levels of non-CpG 
methylation exist in human and rodent tissues, both at the whole genome level and at 
specific promoter regions. Using an adapted Luminometric-based Assay, we detected 
7-13% non-CpG methylation in mouse tissues at the genomic level, and similar levels 
were for specific promoter sequences through different bisulfite sequencing strategies. 
Mitochondrial dysfunction is associated with skeletal muscle insulin resistance in 
Type 2 diabetes and obesity. In Paper II, we show that mitochondria number is 
reduced and mitochondria morphology is altered, in skeletal muscle from Type 2 
diabetic patients. The promoter region of PGC1α, a gene involved in mitochondrial 
biogenesis, was differentially methylated in Type 2 diabetic patients using whole 
genome promoter methylation analysis. Methylation level of PGC1α was negatively 
correlated with mRNA expression. Non-CpG methylation of PGC1α promoter was 
induced in human myotubes by culturing cells in the presence of tumor necrosis factor 
α or free fatty acids. These changes in methylation could be prevented by silencing 
DNA methyltransferase 3B. 
Many morbidly obese individuals undergo gastric bypass surgery as a means to 
reduce daily calorie consumption and lose weight, since conventional strategies for 
obesity treatment are often insufficient. Insulin sensitivity can be dramatically 
improved after the surgery. In Paper III, we report that concomitant with the weight 
loss, the expression of genes involved in mitochondrial function and insulin sensitivity 
in obese subjects was normalized to levels of normal weight controls. Furthermore 
methylation levels of PGC1α and PDK4 promoter regions are altered in obese subjects, 
and methylation of these regions is dynamically changed with weight loss. 
In conclusion, we identify the existence of non-CpG methylation in mammals and 
report a functional role in regulating genes associated with skeletal muscle insulin 
resistance, which is of relevance to the pathogenesis of Type 2 diabetes and obesity. 
We also provide evidence that DNA methylation is dynamically remodeled, 
concomitant with alterations in insulin sensitivity. Environmental factors are potential 
triggers for changes in DNA methylation. 
  
LIST OF PUBLICATIONS 
 
Articles included in this thesis 
 
 
I.  Yan J, Zierath JR, Barrès R. Evidence for non-CpG methylation in mammals. 
Exp Cell Res. 2011 317:2555-2561. 
 
II.  Barrès R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, Krook A, Zierath JR. 
Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls 
mitochondrial density. Cell Metab. 2009 10:189-198. 
 
III.  Barrès R*, Yan J*, Rasmussen M, Krook A, Näslund E, Zierath JR. Weight 
loss after gastric bypass surgery induces epigenetic modifications in human 
obesity. Manuscript submitted.  
(*Both authors contributed equally to this work) 
 
  
Articles not included in this thesis 
 
Barrès R, Yan J, Egan B, Treebak JT, Rasmussen M, Fritz T, Caidahl K, Krook A, 
O'Gorman DJ, Zierath JR. Exercise Remodels Promoter Methylation in Human 
Skeletal Muscle. Manuscript submitted. 
 
Markljung E, Jiang L, Jaffe JD, Mikkelsen TS, Wallerman O, Larhammar M, Zhang 
X, Wang L, Saenz-Vash V, Gnirke A, Lindroth AM, Barrés R, Yan J, Strömberg S, 
De S, Pontén F, Lander ES, Carr SA, Zierath JR, Kullander K, Wadelius C, Lindblad-
Toh K, Andersson G, Hjälm G, Andersson L. ZBED6, a novel transcription factor 
derived from a domesticated DNA transposon regulates IGF2 expression and muscle 
growth. PLoS Biol. 2009 7:e1000256.  
 
Feng X, Yan J, Wang Y, Zierath JR, Nordenskjöld M, Henter JI, Fadeel B, Zheng C. 
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL 
receptor-positive multiple myeloma cells. Mol Immunol. 2010 47:2388-2396. 
 CONTENTS 
 
1 Introduction and background ........................................................................ 1 
1.1 Type 2 diabetes and obesity ................................................................ 1 
1.1.1 General introduction ............................................................... 1 
1.1.2 Diagnostic criteria ................................................................... 1 
1.1.3 Intervention and treatment ...................................................... 2 
 Conventional management ............................................................. 2 
 Gastric bypass surgery .................................................................. 3 
1.1.4 The regulation of metabolism by insulin ............................... 4 
1.1.5 Insulin resistance ..................................................................... 5 
 Fat overload and insulin resistance .................................................. 6 
 Inflammation and insulin resistance ................................................. 7 
1.1.6 Metabolic flexibility in skeletal muscle ................................. 7 
1.1.7 Mitochondrial function ........................................................... 9 
1.1.8 Target genes ............................................................................ 9 
 PGC1α ....................................................................................... 9 
 TFAM ......................................................................................10 
 PDK4.......................................................................................11 
1.2 DNA methylation ..............................................................................11 
1.2.1 Epigenetic modifications ......................................................11 
1.2.2 DNA methylation ..................................................................12 
1.2.3 Non-CpG methylation ..........................................................13 
1.2.4 DNA methyltransferase (DNMT) ........................................14 
2 Present investigation ...................................................................................15 
2.1 Aim of the thesis ...............................................................................15 
2.2 Materials and methods ......................................................................16 
2.2.1 Study participants .................................................................16 
2.2.2 Animal model-The leptin deficient (ob/ob) mice ................17 
2.2.3 Primary human skeletal muscle cell culture ........................18 
2.2.4 Comments on strategies to study DNA methylation ...........18 
 Methylation isoschizomers ..........................................................18 
 Luminometric Methylation Assay (LUMA)  ...................................19 
 MeDIP-qPCR ............................................................................19 
 Methylated DNA enrichment by MBD protein ................................ 20 
 Bisulfite sequencing .................................................................... 21 
2.3 Results and discussion ....................................................................... 24 
2.3.1 Paper I .................................................................................... 24 
 Evidence for non-CpG methylation using adapted LUMA ................. 24 
 Bisulfite sequencing shows significant levels of non-CpG methylation 25 
2.3.2    Paper II ................................................................................... 26 
 PGC1α promoter is hypermethylated in Type 2 diabetic subjects ........ 26 
 PGC1α methylation regulates PGC1α mRNA expression .................. 27 
 Free fatty acids and TNFα induces hypermethylation of PGC1α ......... 28 
 DNMT3B is involved in palmitate-triggered PGC1α hypermethylation 29 
2.3.3    Paper III ................................................................................. 30 
 Clinical characteristics of the study participants ............................... 30 
 The transcription of metabolic genes and DNA methylation pattern ..... 31 
 PGC1α and PDK4 methylation is altered with obesity and weight loss . 31 
3 Summary ...................................................................................................... 35 
4 Conclusion ................................................................................................... 37 
5 Future perspectives ...................................................................................... 38 
5.1 Tissue-specific DNA methylation ..................................................... 38 
5.2 Other epigenetic mechanisms ............................................................ 38 
5.3 Refining definition of ‘epigenetics’ .................................................. 38 
5.4 Linking in utero environmental stimuli to adult metabolic disease . 39 
6 Acknowledgements ..................................................................................... 40 
7 References .................................................................................................... 43 
 
 LIST OF ABBREVIATIONS 
 
BMI 
CREB 
CRP 
DAG 
DMEM 
DMR 
DNA 
DNMTs 
dNTP 
EDL 
EDTA 
EtOH 
FDA 
GAPDH 
GBP 
GI 
GLP-1 
GWAS 
HbA1c 
HDL 
HGF 
HOMA 
Body mass index 
cAMP response element-binding protein 
C-reactive protein 
Diacylglycerol 
Dulbecco’s Modified Eagle Medium 
Differentially methylated region 
Deoxyribonucleic acid 
DNA methyltransferases 
Deoxyribonucleotide triphosphate 
Extensor digitorum longus muscle 
Ethylenediaminetetraacetic acid 
Ethanol 
Food and Drug Administration (U.S.) 
Glyceraldehydes 3-phosphate dehydrogenase 
Gastric bypass surgery 
Gastrointestinal 
Glucagon-like peptide-1 
Genome-wide association study 
Hemoglobin A1c 
High density lipoprotein 
Hepatocyte growth factor 
Homeostatic model assessment 
IFG Impaired fasting glucose 
IGT 
IL6 
LUMA 
MBD 
MeDIP 
MEF 
mRNA 
mtDNA 
NaOAc 
NEFA 
NGT 
NRF 
PBS 
PCR 
PDH 
PDK4 
PGC1α 
PPi 
RNA 
ROS 
RQ 
T2D 
TCA 
TFAM 
TNF-α 
TZD 
WHO 
Impaired glucose tolerance 
Interleukin-6 
Luminometric Methylation Assay 
Methyl-CpG-binding domain 
Methylated DNA ImmunoPrecipitation 
Mouse embryonic fibroblasts 
Messenger RNA 
mitochondrial DNA 
Sodium acetate 
Non-esterified fatty acids 
Normal glucose tolerance 
Nuclear respiratory factor 
Phosphate-buffered saline 
Polymerase Chain Reaction 
Pyruvate dehydrogenase complex 
Pyruvate dehydrogenase kinase isozyme 4, mitochondrial 
Proliferator-activated receptor γ coactivator 1α 
Pyrophosphate 
Ribonucleic acid 
Reactive oxygen species 
Respiratory quotient 
Type 2 diabetes 
Tricarboxylic acid  cycle or Krebs cycle 
Transcription factor A, mitochondrial 
Tumor necrosis factor α 
Thiazolidinediones 
World Health Organization  
  
  
 
Epigenetic Influences on Type 2 diabetes and Obesity 
 
  1 
1 INTRODUCTION AND BACKGROUND 
 
1.1 TYPE 2 DIABETES AND OBESITY  
 
1.1.1 General introduction 
 
The metabolic syndrome is defined by a group of diseases including high blood glucose, 
high blood lipids level, hypertension, central obesity (Haller, 1977; Singer, 1977) 
[Figure 1]. Type 2 diabetes afflicts more than 300 million people worldwide (World 
Health Organization data updated 2011 August). Type 2 diabetes is associated with a 
series of health problems including increased risk of strokes, heart attacks, diabetic 
retinopathy, kidney failure, as well as amputation (Kolata, 1979; Porte and Schwartz, 
1996). Obesity is a major risk for the development of insulin resistance, Type 2 
diabetes, fatty liver disease, cardiovascular disease, degenerative disorders, airway 
disease and some cancers (Haslam and James, 2005; Sims et al., 1973). Type 2 diabetes 
and obesity are multifactorial diseases involving interactions between genetic and 
environmental factors.  
 
 
Figure 1 WHO criteria (1999) of Metabolic Syndrome. (World Health Organization. Definition, diagnosis and 
classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and 
classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999. Available at: 
http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf.) 
 
 
1.1.2 Diagnostic criteria 
 
Type 2 diabetes is defined according to elevated fasting plasma glucose level or 2 hour 
plasma glucose level after a oral glucose tolerance test [Table 1]. HbA1c (hemoglobin 
A1c) is a glycosylated form of hemoglobin and serves as a marker for average blood 
glucose levels over the past 3-4 months. HbA1c ≥6.5% is added as another criterion 
for the diagnosis of diabetes (Executive summary: Standards of medical care in 
diabetes-2010). Overweight and obesity are defined as excessive fat accumulation and 
can be roughly estimated by body mass index (BMI, stands for a person’s weight 
divided by the square of the person’s height, kg/m2). Obesity is classified if a person’s 
BMI is over 30 kg/m
2
 [Table 2].  
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Table 1 WHO (2006) diabetes diagnostic criteria* 
 Fasting glucose 2 hour glucose 
 mmol/L mmol/L 
Normal <6.1 <7.8 
Impaired fasting glucose (IFG) 6.1≤IFG<7.0 <7.8 
Impaired glucose tolerance (IGT) <7.0 ≥7.8 
Diabetes ≥7.0 ≥11.1 
*WHO. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Available at: 
http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf. 
 
Table 2 WHO classification of adult obesity according to BMI* 
BMI Classification 
kg/m2  
<18.5 Underweight 
18.5-24.9 Normal weight 
25.0-29.9 Overweight 
30.0-34.9 Class I Obese 
35.0-39.9 Class II Obese 
≥40.0 Class III Obese 
*WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO 
Technical Report Series 894. Geneva: World Health Organization, 2000. Available at: 
http://whqlibdoc.who.int/trs/WHO_TRS_894.pdf. 
 
1.1.3 Intervention and treatment 
 
1.1.3.1 Conventional management 
 
Management of Type 2 diabetes aims to normalize glucose levels throughout the day, 
such that the development of diabetes-induced complications are reduced or prevented.  
Conventional management of Type 2 diabetes can be summarized into five aspects: 
 Diet control：Low glycemic index diet is recommended. 
 Exercise: Aerobic exercise increases insulin sensitivity and VO2max and reduces 
HbA1c (Zanuso et al., 2010). 
 Medications: Anti-diabetic oral medications include Biguanides, 
Thiazolidinediones (TZD), Sulfonylureas, and alpha-glucosidase inhibitors. 
These medications reduce blood glucose levels either by stimulating insulin 
secretion from the pancreas, increasing target tissue sensitivity to insulin or by 
delaying glucose absorption from the gastrointestinal tract. Metformin (a 
biguanide) is currently the first line medication to treat Type 2 diabetes. Insulin 
therapy is necessary when sufficient control of blood glucose levels cannot be 
achieved only by use of oral medications. Glucagon-like peptide-1 (GLP-1) 
analogs are a new class of drug for treatment of Type 2 diabetes with glucose-
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dependent action (Exenatide approved by FDA in 2005, liraglutide approved by 
FDA in 2010). 
 Education: Adequate information about Type 2 diabetes and relevant training 
should be delivered to newly diagnosed Type 2 diabetic patients. 
 Self-monitoring of blood glucose: It is important for patients to monitor blood 
glucose in order to maintain normal blood glucose level. 
 
The main management of obesity includes dieting and exercise in order to lose weight 
coupled with some form of behavior therapy. Orlistat, a lipase inhibitor, is a medication 
designed to treat obesity by decreasing fat absorption in the intestine. 
 
1.1.3.2 Gastric bypass surgery 
 
Conventional strategies described above for the treatment of Type 2 diabetes and 
obesity, including lifestyle modifications of diet and exercise behavior, are often 
insufficient and pharmacological options are limited (Matthews et al., 1998; Turner et 
al., 1999). When diet and drugs no longer work, many morbidly obese individuals opt 
to undergo bariatric surgery as a means to reduce daily calorie consumption and to lose 
weight. People who have a BMI of 40 kg/m
2
 or higher, or with BMI of 35 kg/m
2
 or 
higher with one or more comorbid conditions can be considered as candidates for 
bariatric surgery according to NIH (National Institutes of Health) recommended criteria 
(NIH, 1992). The preoperative evaluation is still critical for bariatric surgery even 
though the first attempts were performed in the 1950s. 
 
During the last two decades, the vertical banded gastroplasty, gastric banding and 
gastric bypass were the most commonly used procedures in Sweden. In Sweden, 96% 
of all bariatric surgeries performed today are gastric bypass (Scandinavian Obesity 
Surgery Registry) (Marsk, 2009). Gastric bypass entails the creation of a small upper 
pouch of the stomach. This pouch has a volume of about 30 ml. A piece of divided 
jejunum (Roux-limb) is anastomosed to the pouch and the remaining part of the divided 
jejunum is re-attached 1 m distal to the gastro-jejunal anastomosis [Figure 2]. Gastric 
bypass surgery dramatically improves insulin sensitivity and leads to the clinical 
resolution or remission of Type 2 diabetes (Greenway et al., 2002; Rubino et al., 2010; 
Sjostrom et al., 2007). The improvement in insulin sensitivity noted after surgery 
cannot only be explained by weight loss since Type 2 diabetes is resolved even shortly 
after the surgery. Changes in gastrointestinal (GI) peptide release, such as glucagon-like 
peptide-1, after gastric bypass surgery has been proposed to participate in the 
improvement of glucose metabolism, but the underlying molecular mechanism is 
incompletely resolved (Butner et al., 2010; Falken et al., 2011) 
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Figure 2 A schematic drawing of Roux-en-Y gastric bypass procedure for obesity. 
 
1.1.4 The regulation of metabolism by insulin 
 
Insulin is a peptide hormone (51 amino acids in total) and has a molecular weight of 
5808 Da (Sanger and Tuppy, 1951a, b). Insulin is produced within the β-cells of the 
islets of Langerhans in the pancreas (Orci and Unger, 1975; Steiner and Oyer, 1967). In 
the β cells, insulin is synthesized from the precursor molecule proinsulin by removing 
the center of the molecule (C-peptide) through proteolytic enzymes (Steiner and Oyer, 
1967). 
 
Insulin orchestrates fuel homeostasis by stimulating glucose uptake into peripheral 
tissues, inhibiting glucose production by the liver and suppressing stored lipids release 
from adipose tissue. The normal glucose level is tightly controlled, ranging from 4 to 7 
mM, despite the nutritional status (fasting versus fed). Insulin activates the pathways to 
control glucose, free fatty acids, amino acids uptake into cells and promote storage of 
glycogen and lipids, as well as protein synthesis [Figure 3]. 
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Figure 3 The regulation of metabolism by insulin. 
 
1.1.5 Insulin resistance 
 
Skeletal muscle insulin resistance is a common feature of many metabolic disorders 
including Type 2 diabetes, obesity, cardiovascular disease, hypertension and polycystic 
ovary syndrome (Reaven, 2005). 
  
‘Insulin resistance may be said to exist whenever normal concentrations of insulin 
produce a less than normal biologic response. Hormone resistant states may be divided 
into those due to decreased sensitivity to a hormone (i.e., a shift in the dose-response 
curve to the right), those due to a decrease in the maximal response to the hormone, 
and those that are combinations of decreased sensitivity and decreased 
responsiveness.’ (Kahn, 1978) [Figure 4] 
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Figure 4 Types of resistance to hormone action. (Picture redrawn from Kahn CR. Metabolism. 1978 Dec;27(12 
Suppl 2):1893-902.) 
 
Insulin resistance may occur at three levels: 1) Before the interaction of insulin with the 
receptor, such as increased insulin degradation or insulin competing to bind other 
proteins rather than insulin receptor; 2) At the level of the insulin receptor, due to 
alterations in receptor amount or binding affinity; 3) Downstream of the insulin-
receptor interaction, due to a change from hormone-receptor complexes to the final 
biologic effects (Kahn, 1978).  
 
Insulin resistance often precedes the development of overt diabetes. This is due to the 
fact that as insulin resistance develops, the -cell compensates by increasing insulin 
secretion, thus maintaining blood glucose levels within a healthy range. Eventually the 
-cell fails to adequately meet demand, and blood glucose levels rise (Clark et al., 1988; 
Donath and Halban, 2004; Kloppel et al., 1985; Wajchenberg, 2007). 
 
1.1.5.1 Fat overload and insulin resistance 
 
A fat overload theory for the development of insulin resistance has been emerging over 
the past several decades (Griffin et al., 1999; Petersen et al., 1998; Roden et al., 1996). 
A role for free fatty acids in the development of insulin resistance was proposed, based 
on the observations that insulin resistance is associated with elevated free fatty acids 
level in blood (Reaven et al., 1988). Fat is usually stored in adipocytes in the form of 
triglycerides. Ectopic lipid storage contributes to insulin resistance in different tissues 
such as skeletal muscle, pancreas, heart and liver (Boden et al., 2001; Krssak et al., 
1999; Perseghin et al., 1997; Perseghin et al., 1999). Diacylglycerol (DAG) and 
ceramide, intermediates from incomplete β-oxidation, accumulate in muscle cells and 
inhibit insulin signaling pathway (Yu et al., 2002) [Figure 5]. 
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Figure 5 Two general theories to illustrate insulin resistance (Fat overload theory, white background on the 
left side; Inflammation theory, grey background on the right side). 
 
1.1.5.2 Inflammation and insulin resistance 
 
Inflammation is an alternative theory to explain insulin resistance. Unsurprisingly, 
obesity itself is an inflammatory state. Different inflammatory factors secreted from 
adipocytes may attenuate insulin action through enhanced JNK activation in skeletal 
muscle cells. Increased activation of this kinase impairs insulin signaling and glucose 
transport (Hotamisligil et al., 1996; Uysal et al., 1997; Vallerie et al., 2008; Yuan et al., 
2001) [Figure 5]. Macrophages are believed to infiltrate the fat cells and initiate these 
inflammatory responses by secreting cytokines which act on peripheral tissues. 
 
1.1.6 Metabolic flexibility in skeletal muscle 
 
Skeletal muscle comprises 40-50% of the body mass and is the major site of substrate 
metabolism. Skeletal muscle is the primary site for postprandial glucose clearance 
(DeFronzo et al., 1985) and skeletal muscle is the major site of insulin resistance in 
Type 2 diabetic patients [Figure 6] (DeFronzo, 1988). Thus, defects in insulin-
stimulated glucose transport in skeletal muscle account for the whole body insulin 
resistance noted in people with severe obesity or Type 2 diabetes (Dohm et al., 1988; 
Goodyear et al., 1995; Zierath et al., 1994).  
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Figure 6 Glucose uptake in healthy and Type 2 diabetic subjects. (Picture adapted from DeFronzo RA. Lilly 
Lecture 1987. Diabetes. 1988;37:667-687.) 
 
Metabolic flexibility is one of the physiological characteristics of skeletal muscle that 
allows either carbohydrate or fatty acid utilization (Randle et al., 1963). However, in 
skeletal muscle of obese, sedentary individuals there is a narrower range in the switch 
between fat and glucose oxidation compared to aerobically fit and lean individuals 
[Figure 7]. This reduced capacity to the transitions has been described as ‘metabolic 
inflexibility’ of skeletal muscle (Kelley and Mandarino, 2000).  
 
 
Figure 7 Metabolic Flexiblity and Metabolic Inflexibility of skeletal muscle. 
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1.1.7 Mitochondrial function 
  
The human mitochondrial genome encodes 13 proteins, 22 tRNAs and 2rRNAs that 
play an important role in composition of mitochondrial respiratory chain and 
translational machinery (Anderson et al., 1981). Mitochondria, described as the ‘power 
plant’ in cells, regulate metabolism and energy homeostasis by metabolizing nutrients 
and producing ATP. Pyruvate produced from glycolysis is transported to the 
mitochondrial matrix and oxidized to acetyl-CoA, the entry molecular for tricarboxylic 
acid (TCA) cycle or Krebs cycle. Fatty acids are also broken down to acetyl-CoA in 
mitochondria through β-oxidation.  
 
There is ample evidence that mitochondrial dysfunction is associated with skeletal 
muscle insulin resistance in Type 2 diabetes and age-related insulin resistance (Petersen 
et al., 2003; Stump et al., 2003). The underlying mechanism is believed to involve an 
accumulation of intracellular lipid metabolites from incomplete lipid oxidation that 
inhibit insulin signal transduction to glucose transport (Kim et al., 2000; Petersen et al., 
2004; Ritov et al., 2005). Reduced mitochondria number and altered mitochondria 
morphology have been reported in skeletal muscle of Type 2 diabetic patients. 
Mitochondrial DNA (mtDNA) content is decreased in obese subjects compared to lean 
volunteers in skeletal muscle (Ritov et al., 2005). In insulin resistant states, mtDNA 
seems to be vulnerable, probably due to the physiological role of mitochondria to 
produce ROS (Reactive oxygen species) (Linnane et al., 1989). Thus, systemic insulin 
resistance may arise from alterations in the size or number of mitochondria, as well as 
impaired oxidative capacity in skeletal muscle. 
 
There appears to be considerable evidence focused on the correlative nature of the 
relationship between mitochondrial dysfunction and insulin resistance. The theory 
suggesting that insulin resistance comes from impaired fatty acids uptake and oxidation 
in mitochondria has been challenged (An et al., 2004; Monetti et al., 2007). Several 
lines of evidence suggest that obesity-associated glucose intolerance might be due to 
metabolic overload of muscle mitochondria and that skeletal muscle insulin resistance 
may rise from excessive β-oxidation rather than reduced (An et al., 2004; Koves et al., 
2005).   
 
1.1.8 Target genes 
 
This thesis is mainly focused on genes participating in glucose and lipid metabolism, 
specifically genes related to insulin sensitivity and mitochondrial function. Emphasis 
was placed on the PGC-1α, TFAM, and PDK4 as outlined below: 
 
1.1.8.1 PGC-1α 
 
PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) contains 798 
amino acids in the human sequence (797 in the mouse sequence). The encoded gene 
PPARGC1 is located on chromosome 4 in human (chromosome 5 in mouse). PGC-1 
was first identified as a transcriptional coactivator regulating adipocyte differentiation 
through interacting with nuclear receptor PPARγ (Puigserver et al., 1998). PGC-1α is 
highly expressed in brown adipose tissue, skeletal muscle and heart and at a relatively 
low level in white adipose tissue and liver (Puigserver et al., 1998). PGC1α interacts 
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with multiple transcription factors [Table 3] including cAMP response element-binding 
protein (CREB) and nuclear respiratory factors (NRFs) and plays a critical role in 
linking nuclear receptors to adaptive thermogenesis, mitochondrial biogenesis and 
muscle fiber type switching (Lin et al., 2002; Puigserver et al., 1998; Wu et al., 1999b).  
 
Table 3 Selected transcription factors with which PGC-1α works as a coactivator 
Transcription Factor Function Reference 
NRF1 Mitochondrial biogenesis (Wu et al., 1999b) 
ERR-α Mitochondrial biogenesis (Mootha et al., 2004) 
PPAR-α Fatty acid oxidation (Vega et al., 2000) 
PPAR-δ Fatty acid oxidation (Wang et al., 2003) 
PPAR-γ Brown adipocyte differentiation; 
UCP-1 induction 
(Puigserver et al., 1998) 
GR Gluconeogenesis (Knutti et al., 2000) 
HNF-4α Gluconeogenesis (Yoon et al., 2001) 
FOXO1 Gluconeogenesis (Puigserver et al., 2003) 
NRF, nuclear respiratory factor; ERR, estrogen-related receptor; PPAR, peroxisome proliferator-activated 
receptor; GR, glucocorticoid receptor; HNF, hepatic nuclear factor; FOXO1, forkhead box O1. 
 
PGC1α stimulates mitochondrial biogenesis and respiration in skeletal muscle cells 
(Wu et al., 1999b). Two DNA array studies have shown that PGC-1α is downregulated 
in skeletal muscle obtained from Type 2 diabetic patients (Mootha et al., 2003; Patti et 
al., 2003). A common polymorphism in the coding region of the PPARGC1A gene 
(Gly482Ser) leading to gene expression defect is associated with the risk of Type 2 
diabetes, which provides a direct link between PGC1α function and disease outcome 
(Yang et al., 2011). In contrast to these studies, mRNA expression levels of PGC1α, 
NRF-1 and NRF-2 were not altered in insulin-resistant offspring (Morino et al., 2005). 
These data suggest there may be additional unknown factors important in the regulation 
of mitochondrial biogenesis.  
 
1.1.8.2 TFAM 
 
This gene encodes Transcription factor A, mitochondrial (TFAM), which is 
important for mitochondrial transcription, as well as mitochondrial genome replication. 
TFAM contains 204 amino acids and was identified for its ability to activate 
mitochondrial DNA promoters in experiments where human TFAM was cloned into 
bacteria (Parisi and Clayton, 1991). Furthermore, in vivo studies demonstrate TFAM is 
critical for regulating mitochondrial DNA (mtDNA) copy number and maintaining 
mitochondrial biogenesis, as well as embryonic development (Larsson et al., 1998). 
Given that TFAM shares DNA packaging ability feature with the high mobility group 
(HMG) proteins,  and  that TFAM may be 1700 fold more abundant than mtDNA 
(Takamatsu et al., 2002), it is likely that TFAM is involved in forming nucleoid 
structures to keep mtDNA integrity (Kang et al., 2007). The observation that mtDNA is 
not detected in homozygous Tfam knockout mice provides a direct link between TFAM 
biological function and mtDNA (Larsson et al., 1998). 
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1.1.8.3 PDK4 
 
Pyruvate dehydrogenase kinase isozyme 4, mitochondrial is an isozyme of pyruvate 
dehydrogenase kinase encoded by PDK4 gene (Rowles et al., 1996). The PDK4 protein 
is located in the mitochondrial matrix and suppresses conversion from pyruvate to 
acetyl-CoA by inhibiting pyruvate dehydrogenase complex (PDH), which is the rate-
limiting step in the regulation of glucose oxidation in muscle [Figure 8]. In skeletal 
muscle, PDK4 is induced by exercise (Hildebrandt et al., 2003; Pilegaard et al., 2000), 
starvation, as well as diabetes (Wu et al., 1999a) concomitant with inactivation of 
pyruvate dehydrogenase complex.  
 
 
 
 
Figure 8 PDK4 is a negative regulator in glucose oxidation in skeletal muscle. PDH, pyruvate dehydrogenase; 
CD36, fatty acid translocase; CPT1, carnitine palmitoyl transferase 1; TCA, tricarboxylic acid cycle. 
 
 
1.2 DNA METHYLATION 
 
1.2.1 Epigenetic modifications 
 
The term ‘Epigenetics’ was first coined by the developmental biologist and evolutionist 
Conrad H. Waddington (1905-1975) aiming to emphasize the mechanism driving the 
genotype to the phenotype during development (Waddington, C. H. The Strategy of the 
Genes, Allen & Unwin, London, 1957). The definition has been changed and refined 
from time to time. The commonly accepted definition was described by Arthur Rigs 
and colleagues, ‘the study of mitotically and/or meiotically heritable changes in gene 
function that cannot be explained by changes in DNA sequence’ (Russo, V.E.A., 
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Martienssen, R.A. & Riggs, A.D. Epigenetic Mechanisms of Gene Regulation, Cold 
Spring Harbor Laboratory Press, Woodbury, 1996). According to this definition, 
epigenetics refers to modifications ‘above the genetics’ and it has three characteristics: 
① modifications are superimposed on DNA or histones (proteins package DNA); ② 
the DNA sequence itself does not change; ③ modifications could affect gene activity. 
Key events have been discovered in the field of epigenetics in the past seven decades 
[Figure 9] and scientists are dedicated to map the human epigenome.  
 
 
 
Figure 9 Timeline of key events and discoveries in the field of epigenetics. HATs, histone acetylases; HDACs, 
histone decetylases; DNMTs, DNA methyltransferases; miRNA, microRNA. Picture adapted from (Zaidi et al., 
2011). 
 
A close relationship has been hypothesized to exist between epigenetic modifications 
and environmental factors. A number of studies have been found to support this 
hypothesis. For example, maternal care such as licking and nursing behavior in rats can 
influence epigenetic markers of the glucocorticoid receptor promoter and further affect 
offspring behaviors (Weaver et al., 2004). Disease susceptibility is not the same in 
monozygotic twins in the face of what appears to be similar environments. This 
indicates epigenetic differences that arise during ageing may play a role in disease 
development. Young twin pairs have similar distribution of DNA methylation through 
the genome, whereas older twin pairs show marked differences in the amount and 
pattern of DNA methylation (Fraga et al., 2005).  
 
1.2.2 DNA methylation 
 
DNA methylation and histone tail modifications are two major epigenetic 
modifications that could control and regulate genes at different layers. DNA 
methylation occurs on the 5 position of the pyrimidine ring of cytosine. DNA 
methylation has been widely related to imprinting, mammalian development and 
genomic stability maintenance (Kurukuti et al., 2006; Reik et al., 2001). In particular, 
5-methyl cytosine followed by guanosine (CpG dinucleotide) is the dominate type of 
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methylation pattern in mammals. Furthermore, CpG sites are usually clustered (also 
known as CpG islands) in the promoter regions of many genes to modulate gene 
expression by blocking transcription factor access to DNA [Figure 10]. 
 
DNA methylation is considered to be established early in embryonic stage and remains 
dynamic only during cell division and differentiation. A number of cell type-specific 
DNA methylation patterns are created during this period of development. 
Environmental events and nutritional conditions may induce permanent DNA 
methylation mark changes in utero and these adaptive changes can have a lasting 
impact on adult disease later (Barker et al., 1989). The potential plasticity of DNA 
methylation also enables reprogramming, depending on exposure to nutritional, 
chemical, and environmental factors. 
 
 
 
 
 
 
 
1.2.3 Non-CpG methylation 
 
5-methyl cytosine accounts for around 1% of total DNA bases in human somatic cells 
and 70-80% of CpG dinucleotides are methylated through the genome (Ehrlich et al., 
1982). Several studies have been performed to elucidate the role of CpG methylation in 
regulating gene expression in human diseases. Non-CpG methylation (refering to 
methylated cytosine within CpA, CpT or CpC) has been reported in plants and 
embryonic stem cells (Grandjean et al., 2007; Meyer et al., 1994; Ramsahoye et al., 
2000). Nevertheless, more attention has been paid to the physiological role of cytosine 
methylation in non-CpG contexts. More abundant non-CpG methylation than originally 
anticipated has been identified in human embryonic stem cells through a genome-wide, 
single-base-resolution approach, suggesting non-CpG methylation may play a critical 
role in regulating gene expression in cells that have the potential to differentiate (Lister 
et al., 2009). 
 
Environmental factors 
 
 
DNA methylation 
 
 
    Transcription complex 
 
B 
 
 
 
silent 
Transcription  No transcription 
A active 
Figure 10 Regulation of gene expression by DNA methylation. By modifying DNA methylation, 
environmental factors may alter the binding of transcription complexes, thus leading to inhibition of gene 
expression. 
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1.2.4 DNA methyltransferase (DNMT) 
 
The enzymes which catalyze the addition of methyl groups to cytosine, DNA 
methyltransferases (DNMT1, DNMT3A and DNMT3B) have been identified (Xie et 
al., 1999; Yen et al., 1992). A fourth enzyme previously named as DNMT2 was shown 
to be tRNA methyltransferase and does not methylate DNA (Goll et al., 2006). 
DNMT1 is thought to be responsible for maintenance of methylation during DNA 
synthesis, and DNMT3A and DNMT3B are required for de novo methylation (Bestor 
and Ingram, 1983; Okano et al., 1999). The fundamental mechanism of DNMTs is still 
unclear. Biochemical studies demonstrated the DNA methylation process was based on 
the enzymatic reaction by forming transient covalent complex between DNMT1 and 
targeted cytosine (Santi et al., 1983) [Figure 11]. The rationale for maintaining and 
modifying the specific DNA methylation pattern is complicated to understand due to 
the fact that the methylation process itself depends on multiple factors including 
interactions between different methyltransferases, nuclear factors, chromatin structure, 
as well as methyl donors.  
 
 
 
Figure 11 Demonstration of DNA methylation reaction [Take DNMT1 for example, red in the picture]. 
Unmethylated and methylated cytosines are shown in white and dark circles. Picture redrawn from 
(Schermelleh et al., 2005). 
 
Epigenetics is not only involved in normal development, but also disease progression. 
Meanwhile, the diversity of phenotypes in the population is unlikely to be explained by 
genetics alone. The concept of epigenetics emerges to provide a potential mechanism 
for different susceptibilities to a disease, as well as a link between environmental 
factors and diseases consequences. Numerous genes can become abnormally 
methylated during the development of tumors (Bedford and van Helden, 1987; Cheng 
et al., 1997; Kim et al., 1994; Lin et al., 2001; Wahlfors et al., 1992). Epigenetics may 
establish a better understanding of the etiology of Type 2 diabetes and obesity and 
provide a rational model to explain the mechanism by which environmental factors 
(diet/nutrition, exercise, smoking, stress etc.) influence metabolic diseases.  
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2 PRESENT INVESTIGATION 
 
2.1 AIM OF THE THESIS 
 
Type 2 diabetes and obesity are multifactorial diseases involving interactions between 
genetic and environmental influences. Based on GWAS (genome-wide association 
study), a number of gene defects due to coding sequence changes have been shown to 
contribute to metabolic diseases (Brito et al., 2009; Franks et al., 2007a; Ruchat et al., 
2010). For examples, a common FTO variant (rs9939609) has been associated with 
Type 2 diabetes in multiple populations by increasing obesity risk (Frayling et al., 
2007). There is also a strong inheritance risk for Type 2 diabetes. Those with first-
degree relatives suffering from Type 2 diabetes have a much higher risk to develop 
Type 2 diabetes (Deo et al., 2006; Mills et al., 2010). However, genetics alone is 
unlikely to explain the different susceptibilities to diseases in a population. The genetic 
variants identified in GWAS generally provide an explanation for only a fraction of the 
cases of metabolic diseases. Genotype-environment interactions may contribute to the 
understanding of complexity of human diseases (Eichler et al., 2010; Franks et al., 
2007b; Manolio et al., 2009). 
 
A major challenge is to gain evidence linking environmental and nutritional factors to 
the control of gene expression. Epigenetics provides a rationale framework to 
understand the etiology of Type 2 diabetes and obesity from another point of view. In 
this thesis, emphasis has been placed on the role of DNA methylation, a major 
epigenetic modification, involved in Type 2 diabetes and obesity. Specific aims for this 
thesis are:  
  
1. To investigate the existence of cytosine methylation on non-CpG sequences in 
mammals.  
2. To characterize the role of DNA methylation in Type 2 diabetes.  
3. To determine if DNA methylation is altered following weight loss induced by 
gastric bypass surgery in human obesity.  
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2.2 MATERIALS AND METHODS 
 
2.2.1 Study participants 
 
This thesis is based on studies of human material and tissue biopsies. These unique and 
precious samples allow for a direct study of human disease. All experiments performed 
in this thesis work have been approved by the Local Ethics Committee. Informed 
written consent was obtained from all participants before any testing was initiated. In 
Paper II, we studied male subjects with normal glucose tolerance (NGT) or impaired 
glucose tolerance (IGT) and Type 2 diabetic patients (T2D). The diagnosis was 
confirmed according to clinical data before the study was initiated. Type 2 diabetic 
patients were treated with diet, metformin or sulfonylureas. Patients were excluded 
from the study if under treatment with β-blockers, ACE inhibitors or hormone therapy. 
The level of fasting glucose and hemoglobin A1c in Type 2 diabetic patients was 
significantly higher than the other two groups. Age, BMI, triglycerides and VO2max 
were matched in all three groups [Table 4]. 
 
Table 4 Clinical characteristics of participants in Paper II 
 
 
N 
Age 
(years) 
BMI 
(kg/m2) 
Fasting glucose 
(mM) 
Hemoglobin 
A1c (%) 
Triglycerides 
(mmol/L) 
VO2max 
(L/min) 
NGT 15 57±2 26.4±0.6 5.0±0.1 4.6±0.1 1.25±0.21 2.2±0.2 
IGT 8 60±2 28.0±0.9 5.5±0.6 4.8±0.3 1.34±0.52 2.3±0.2 
T2D 15 59±2 27.7±0.6 8.3±0.4* 6.4±0.3* 1.35±0.12 2.2±0.1 
Results are mean±SEM, for subjects with Normal Glucose Tolerance (NGT), Impaired Glucose Tolerance 
(IGT) or Type 2 Diabetes (T2DM). *P<10-7. 
 
In Paper III, we studied eight non-diabetic obese women (mean BMI=42.1 kg/m
2
) 
who underwent gastric bypass surgery. The homeostatic model assessment (HOMA) 
values indicate insulin resistance and β-cell functional defects in obese participants. 
Laparoscopic Roux-en-Y gastric bypass (Lonroth et al., 1996; Wittgrove et al., 1996; 
Wittgrove et al., 1994) was performed in this study. Sixteen normal weight women 
were studied as a control group. The level of insulin, triglycerides, high density 
lipoprotein (HDL), and non-esterified fatty acids (NEFA) in the obese women was 
significantly different compared to the normal weight subjects. Leptin, interleukin-6 
(IL6), hepatocyte growth factor (HGF) and C-reactive protein (CRP) were increased 
with obesity. Dramatic weight loss was induced by the surgery from 122.3 kg (mean 
value) before surgery to 88.1 kg (mean value) after surgery. Furthermore, fasting 
glucose, insulin, lipids levels, inflammatory factors were normalized after gastric 
bypass surgery [Table 5]. 
 
Skeletal muscle biopsies (50-100 mg) were obtained from vastus lateralis portion of the 
quadriceps femoris muscle either under local anesthesia (Lidocaine hydrochloride) or 
under general anesthesia, before the surgery was initiated. 
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Table 5 Anthropometric and clinical characteristics of the participants in Paper III 
 
 
Obese Women 
(n=8) 
Lean Women 
(n=16) 
 
Before Surgery After Surgery 
 
Age – yr 42±4 42±4 40±3 
Weight – kg 122.3±4.1
††
 88.1±6.6
**,††
 70.1±2.8 
Body mass index – kg/m2 42.1±1.5
††
 31.2±1.6
**,††
 25.0±0.8 
Fasting plasma glucose – mmol/L 5.6±0.3 4.8±0.2
*
 5.0±0.1 
Insulin – pmol/L 105.2±17.8
††
 59.2±8.6
*,†
 40.8±3.6 
HOMA-IR 4.4±0.8
††
 2.1±0.3
*
 1.5±0.2 
Plasma Cholesterol – mmol/L    
Total 5.05±0.37 4.13±0.34
*
 3.84±0.22 
Low density lipoprotein  3.23±0.31 2.35±0.35
*
 2.85±0.21 
High density lipoprotein 1.14±0.06
††
 1.36±0.12 1.61±0.12 
Triglyceride – mmol/L 1.57±0.26
†
 0.89±0.13
*
 1.03±0.15 
Non-esterified fatty acids – mmol/L 0.62±0.05
†
 0.39±0.08
*
 0.36±0.08 
Leptin – ng/ml 60.6±7.4
††
 21.3±6.9
**
 10.7±3.4 
Interleukin-6 – pg/ml  4.80±0.73
†
 4.17±1.39 2.00±0.59 
Interleukin-8 – pg/ml 3.96±2.05 2.42±0.85 2.23±0.22 
Monocyte chemotactic protein-1 – 
pg/ml 
127.2±14.4
†
 98.8±18.3
*,††
 243.3±26.7 
Hepatocyte growth factor – pg/ml 1,371±588
†
 587±128
†
 264±57 
C-reactive protein - ng/ml 1,227±85
††
 476±120
**
 313±112 
TNF-α – pg/ml 4.6±0.7 4.2±0.7 3.3±0.5 
Results are mean±SEM. Differences before versus after surgery were determined using a paired Students t-
test. *P<0.05, **P<0.001 versus before surgery. Differences between obese and normal weight (lean) women 
were determined using an unpaired Students t-test. †P<0.05, ††P<0.005 versus normal weight (lean) women. 
 
2.2.2 Animal model-The leptin deficient (ob/ob) mice 
 
Leptin is encoded by the ob gene and regulates energy balance in the mouse (Zhang et 
al., 1994). Leptin inhibits appetite through acting on its receptors in the hypothalamus 
of the brain. Thus, leptin deficiency will lead to a failure to control food intake, and this 
will ultimately lead to obesity. The leptin-deficient ob/ob mouse is characterized by 
obesity, hyperphagia, hyperglycemia, hyperinsulinemia, hyperlipidemia and insulin 
resistance, and is widely used to study Type 2 diabetes, obesity and other metabolic 
diseases (Huang et al., 2011; Hue et al., 2009; Mark et al., 1999; Okada et al., 2007; 
Wendel et al., 2010). 
 
Female ob/ob mice and their lean littermate controls were used in Paper I. Animals 
were generated on a C57BL/6J background. Animals were housed with free access to 
food and water. Room temperature and humidity were maintained stable and under a 
12-hour light/dark cycle. Experiments were performed with approval from the Regional 
Animal Ethical Committee Stockholm, Sweden. Extensor digitorum longus (EDL) 
muscle, soleus muscle, heart, liver, different fat pads were carefully dissected from 13 
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week old mice. Tissues were dissected from visible blood vessels and immediately 
frozen in liquid nitrogen. 
 
2.2.3 Primary human skeletal muscle cell culture 
 
Satellite cells were isolated from human skeletal biopsies using trypsin digestion. 
Vastus lateralis muscle biopsies from people with normal glucose tolerance were 
placed in cold phosphate-buffered saline (PBS) supplemented with 1% PeSt (100 
units/ml penicillin, 100μg/ml streptomycin) and kept in the freezer for one day. Then 
biopsies were dissected free from visible connective and fat tissue, finely sliced, mixed 
with trypsin-EDTA and finally incubated with agitation at 37°C for 10 minutes. The 
supernatant containing liberated satellite cells was collected and transferred to growth 
medium (DMEM/Ham’s F12 medium supplemented with 20% fetal bovine serum 
(FBS), 1% PeSt and 1% Fungizone). The remaining tissue was repeatedly digested. 
The satellite cells were pooled and incubated with non-coated petri dish for 1 hour for 
37°C to remove non-myogenic (fast adherent) cells contamination. The supernatant 
containing satellite cells was cultured in culture flasks. Growth medium was changed 
every second day. Subculture 4-5 passages were used for experiments. Confluent (90%) 
myoblasts were initiated to differentiate into myotubes by changing to differentiation 
medium (DMEM supplemented with 4% FBS, 1% PeSt and 1% Fungizone) for two 
days. Then cells were cultured in lower serum level (2% FBS) medium for another 
three days. During the last 48 hours of differentiation, cells were treated with factors 
have been known to induce insulin resistance, 120 nM insulin, 20 mM glucose, 1 μM 
tumor necrosis factor α (TNF-α), 0.5 mM palmitate or 0.5 mM oleate. 
 
2.2.4 Comments on strategies to study DNA methylation 
 
The methods used for Paper I-III can be found in section “Material and Method” from 
each respective paper. Paper I specifically addressed methods used to demonstrate 
non-CpG methylation in mammals. Currently, there is a wide range of methods aiming 
to measure global methylation level and also methylation status of specific sequences. 
Some different approaches to study DNA methylation will be described and 
commented on in this thesis offering clarity to the results presented in this work.  
 
2.2.4.1 Methylation isoschizomers 
 
Isoschizomers are pairs of restriction enzymes which recognize the same DNA 
sequence. In some special cases, one of a pair of isoschizomers recognizes and cleaves 
both the methylated and unmethylated form of the same sequence (methylation-
insensitive endonuclease). The other isoschizomer is only able to cut the unmethylated 
form (methylation-sensitive endonuclease). Several methylation assays generally 
utilized this property to distinguish the methylation state of the specific restriction site. 
Two isoschizomers, HpaII and MspI, specifically digest DNA at a CCGG sequence and 
are generally used to determine the genome-wide CpG methylation level. If the internal 
cytosine is methylated (C
m
CGG), HpaII is unable to digest, whereas MspI is insensitive 
to methylation status. Different techniques have been developed to estimate the CpG 
methylation level following enzyme digestion in a CCGG context. Similarly, Psp6I and 
AjnI are isoschizomers for the sequence CCWGG (W=A or T). Psp6I is methylation 
sensitive and AjnI is not in the context of C
m
CWGG.  
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2.2.4.2 Luminometric Methylation Assay (LUMA) 
 
The Luminometric Methylation Assay (LUMA) method [Figure 12] is based on 
methylation-sensitive enzymes digestion and following polymerase extension assay by 
the Pyrosequencing method (Karimi et al., 2006).  Briefly, 500 to 1000 ng of genomic 
DNA samples were digested in two reactions HpaII+EcoRI and MspI+EcoRI in 
Tango® buffer for 4 hours at 37°C for a complete digestion. Samples were then 
transferred to 96 well Pyrosequencing plates and Pyrosequencing Annealing Buffer 
was added to each reaction. Pyrophosphate (PPi) was released when DNA polymerase 
incorporates deoxyribonucleotide triphosphate (dNTP) into the complementary 
template strand. ATP sulfurylase converts PPi to ATP in the presence of adenosine 5’ 
phosphosulfate (APS) and ATP drives luciferase-mediated conversion of luciferin to 
oxyluciferin generating visible light, which is proportional to the amount of ATP. Thus, 
the amount of nucleotides incorporated can be estimated by the height of peak value 
(light signal). Results were obtained from a Pyrosequencer machine and the %CCGG 
methylation level was calculated with the following equation: [1-
(HpaII/EcoRI)/(MspI/EcoRI)]x100. 
 
 
Figure 12 Principle of LUMA method based on enzyme digestion and Pyrosequencing. Picture adapted from 
(Karimi et al., 2006). PPi, pyrophosphate; APS, adenosine 5’ phosphosulfate. 
 
2.2.4.3 MeDIP-qPCR 
 
Methylated DNA immunoprecipitation (MeDIP) is a large-scale technique isolating 
methylated DNA fragments via an antibody against 5-methylcytosine. Purified 
genomic DNA prepared from cultured cells or tissue samples is either digested with 
restriction enzyme or sonicated into small fragments. Single-stranded DNA and 
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appropriate fragment size are critical elements to enhance antibody binding affinity. 
After denaturation, DNA fragments are incubated with monoclonal 5-methylcytosine 
antibodies, which can be captured by magnetic beads conjugated to anti-mouse-IgG.  
Immunoprecipitated DNA is then recovered with Proteinase K digestion followed by 
column-based purification [Figure 13]. Based on the principle that the antibody 
recognizes and binds to 5-methylcytosine, both CpG methylation and non-CpG 
methylation can be determined. Downstream epigenetic applications to assess 
methylated DNA include real-time Polymerase Chain Reaction (MeDIP-qPCR), array-
based hybridization (MeDIP-chip) and high-throughput sequencing (MeDIP-seq).  
 
 
Figure 13 MeDIP flow chart. 
 
2.2.4.4 Methylated DNA enrichment by MBD protein 
 
Another methylated DNA enrichment protocol is supplied by the MethylMiner kit 
(Invitrogen). The capture reaction is performed by adding fragmented DNA to the 
MBD (Methyl-CpG-binding domain)-magnetic beads. Unbound DNA is removed in 
the supernatant. The methylated DNA is eluted as a single fraction with a high-salt 
elution buffer (2000mM NaCl) and precipitated using NaOAc and EtOH precipitation. 
The MethylMiner kit captures both CpG methylated DNA and non-CpG methylated 
DNA fragments (Dr. Romain Barrѐs, personal communication). We also validated the 
MethylMiner kit before initiating experiments using input genomic DNA mixed with 
methylated and non-methylated fragments according to the protocol. PCR was 
performed on the different fractions from the procedure amplified by specific primers 
to detect non-methylated or methylated sequences. The non-captured fraction was only 
detected as non-methylated DNA and the eluted fraction was captured as methylated 
DNA, which indicates the MethylMiner kit is able to exclusively isolate the methylated 
DNA [Figure 14].  
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Compared to antibody-based methods, MBD binding revealed a high affinity for 
methylated DNA. Given that the low amount of DNA materials obtained from cells or 
tissues, the MBD-based method is much more sensitive than antibody-based methods. 
These two commonly used approaches have been compared in a prostate cancer study 
to enrich methylated DNA regions of the genome and discover differentially 
methylated regions (DMRs). The results provide evidence that MeDIP commonly 
enriched for methylated regions with a low CpG density, while MBD captured is 
usually identified by high CpG density regions (Nair et al., 2011). 
 
 
Figure 14 Validation of MethylMiner DNA enrichment kit. The lanes are as follows: Input, genomic DNA+mix 
of non-methylated and methylated DNA; Non-captured, non-captured (unbound) DNA fraction; Wash 1, 
Wash 2, washing steps; Eluted, high salt elution fraction. PCR was performed on the different fractions from 
the procedure amplified by specific primers to detect non-methylated or methylated sequences. 
 
2.2.4.5 Bisulfite sequencing 
 
Bisulfite sequencing (i.e. applying routine sequencing methods to bisulfite treated 
DNA) is the most powerful method to detect cytosine methylation in a site-specific 
manner (Frommer et al., 1992). Bisulfite treatment of the DNA template converts 
cytosine residues to uracil, but has no effect on 5-methylcytosine residues (Hayatsu et 
al., 1970; Shapiro et al., 1973) [Figure 15]. Based on this principle, bisulfite treatment 
could introduce specific changes in the DNA sequence through chemical modifications 
in the presence of sodium bisulfite and this will provide information at the single-
nucleotide level regarding the DNA methylation state.  
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Figure 15 Bisulfite-mediated conversion of cytosine to uracil. 
 
To analyze bisulfite-treated DNA material, we utilized PCR and standard DNA 
sequencing approaches to detect the specific methylation sites. This approach requires 
cloning of PCR products before DNA sequencing to obtain adequate sensitivity. 
Primers flanking the region of interest are designed to be only complementary to 
bisulfite-treated DNA and amplify both methylated and unmethylated sequences. In the 
sense strand, unmethylated cytosines are shown as thymines and as adenines in the 
antisense strand instead [Figure 16].  
 
A major challenge with the bisulfite sequencing technique is incomplete conversion. If 
the conversion process of each individual cytosine to uracil is incomplete, this will 
increase the chance of reporting false positive methylation levels. This is due to 
interpreting unconverted unmethylated cytosines to methylated cytosines. Bisulfite has 
better access to single-stranded DNA templates (Fraga and Esteller, 2002), which 
allows for complete conversion. To maintain DNA in a single-stranded form, and 
prevent denatured DNA strands renaturating during bisulfite treatment, a modified 
approach (Olek et al., 1996) based on DNA material embedded in low melting point 
(LMP) agarose to facilitate the bisulfite conversions and also avoid losing DNA 
materials was used. 
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Figure 16 Rationale for bisulfite sequencing. Methylated cytosine in red (C) and unmethylated cytosine in blue 
(C).  5meCpG;  5meCpA;  5meCpT;  5meCpC. 
 
Another concern is the degradation of DNA material due to the bisulfite treatment 
conditions to ensure complete conversion, such as a long incubation time, elevated 
temperature and high chemical concentration. The lack of intact DNA templates could 
lead to subsequent PCR amplification failure. Thereafter, optimizing the bisulfite 
conditions to minimum DNA degradation is critical.  
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 Paper I 
 
Evidence for non-CpG methylation in mammals 
 
Non-CpG methylation (cytosine methylation within CpA, CpT or CpC context) has 
been identified in plants (Meyer et al., 1994) and mammalian embryonic stem cells 
(Ramsahoye et al., 2000). The existence of non-CpG methylation in mammalian tissues 
is still under discussion.  
 
2.3.1.1 Evidence for non-CpG methylation using adapted LUMA 
 
We adapted the conventional LUMA to determine global non-CpG methylation levels 
in CCWGG (W=A/T) context. The adapted method was combined with restriction 
enzyme digestion (Psp6I is methylation sensitive and AjnI is methylation insensitive) 
and Pyrosequencing [Figure 17]. Pyrophosphate (PPi) was released when DNA 
polymerase incorporates deoxyribonucleotide triphosphate (dNTP) into the 
complementary template strand. ATP sulfurylase converts PPi to ATP in the presence 
of adenosine 5’ phosphosulfate (APS) and ATP drives luciferase-mediated conversion 
of luciferin to oxyluciferin generating visible light that is proportional to the amount of 
ATP. Thus, the amount of nucleotides incorporated can be estimated by the height of 
peak value (light signal). Results were obtained from pyrosequencing and the 
%CCWGG methylation level calculated with the following equation: [1-
Psp6I/AjnI]x100. 
 
To test the linearity of this adapted assay, we applied the approach using synthetic 
DNA with different known methylation levels. The results were highly linear 
(R
2
=0.915). Further validation was performed using 3T3 fibroblasts and mouse 
embryonic fibroblasts (MEF). Eight percent of cytosines were observed to be 
methylated in non-CpG motifs in MEF, whereas 1% in 3T3 fibroblasts, which was 
consistent with previous findings (Lister et al., 2009; Ramsahoye et al., 2000). 
Surprisingly, substantial cytosine methylation levels in CCWGG context were also 
detected in several adult mouse tissues in Paper I, 7.2% in EDL, 7.7% in soleus, 8.5% 
in liver, 7.0% in fat and 13.2% in heart. 
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Figure 17 Illustration for adapted LUMA method to detect global non-CpG methylation in CCWGG context. 
 
2.3.1.2 Bisulfite sequencing shows significant levels of non-CpG methylation 
 
C
m
CWGG might not represent all non-CpG methylation sites. Bisulfite sequencing, the 
gold standard method to investigate DNA methylation, provides single-nucleotide 
resolution information regarding the DNA methylation state. Non-CpG methylation of 
the TFAM promoter and GAPDH promoter (glyceraldehydes 3-phosphate 
dehydrogenase promoter containing a high content of cytosines) was determined in 
human skeletal muscle to be 2.6% and 0.8% respectively. Our data provides evidence 
that non-CpG methylation is unevenly distributed through genome, thus implying site-
specific physiological importance of non-CpG methylation rich regions spanning the 5’ 
end of the regulatory regions of specific genes.  
 
Incomplete conversion in bisulfite sequencing is a challenging caveat that might 
overestimate the methylation levels since unconverted unmethylated cytosines are 
interpreted as methylated cytosines. Bisulfite modification of the TFAM promoter was 
performed using various protocols and commercially available kits. Applying different 
approaches, we revealed similar level of non-CpG methylated cytosines, that 
corresponds to 2.2% using the original protocol (Frommer et al., 1992), 2.6% for 
commercial kit and 2.8% using a low melting point (LMP) agarose approach (Olek et 
al., 1996). A further control was also included to discriminate the actual presence of 
non-CpG methylation from the incomplete conversion background. The strategy 
involved spiking a single copy level of unmethylated human template of TFAM 
promoter generated by PCR into mouse genomic DNA, by which an unmethylated 
template could be bisulfite treated and denatured in genomic surroundings. We found 
0.9% incomplete conversion using this control and defined this as our background for 
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TFAM, which also indicated the observed non-CpG methylation levels in human 
skeletal muscle are above background threshold. 
 
Our data demonstrates non-CpG methylation contributes to the total DNA methylation 
in mammals. Indeed, the few reports focusing on non-CpG methylation in mammals 
are conflicting and non-CpG methylation is often overlooked due to methodological 
differences (Grandjean et al., 2007; Lister et al., 2009). Typically, two rounds of PCR 
are applied and this could partially explain the conflicting results. Bisulfite sequencing 
primer design excludes CpG sites and assumes other cytosines to be unmethylated, thus 
resultant primers have a higher affinity to and are prone to amplify unmethylated 
templates. 
 
The pervasive DNA methylation in non-CpG contexts in embryonic stem cells (Lister 
et al., 2009) suggested a role for carrying and maintaining the pluripotent ability in 
cells. Future work will be needed to explore the prevalence of non-CpG methylation 
and different methylation patterns in various somatic mammalian tissues.   
 
 
2.3.2 Paper II 
 
Non-CpG methylation of the PGC1α promoter through DNMT3B controls 
mitochondrial density 
 
Epigenetic modifications of the genome, including DNA methylation, provide a 
potential molecular basis for the interaction between genetic and environment factors 
on glucose homeostasis and may contribute to the manifestation of Type 2 diabetes. 
Here we determined whether change in promoter methylation is associated with insulin 
resistance.  
 
2.3.2.1 PGC1α promoter is hypermethylated in Type 2 diabetic subjects 
 
To have a whole picture of genome promoter DNA methylation patterns and further 
investigate candidate genes for methylation change specifically in Type 2 diabetes, we 
performed a MeDIP array (Methylated DNA immunoprecipitation followed by 
microarray technology) on vastus lateralis skeletal muscle obtained from Type 2 
diabetic patients (T2D) or normal glucose tolerant subjects (NGT). We discovered 838 
gene promoter regions were differentially methylated in Type 2 diabetes (out of 25,500 
promoter regions represented on the array), of which 44 positive promoter regions were 
identified to be related to mitochondrial structure and function. Particularly, cytosine 
hypermethylation of Peroxisome Proliferator-Activated Receptor γ Coactivator-1 α 
(PGC-1α) was found in Type 2 diabetic patients.  
 
We next validated our MeDIP result for the region covering the PGC-1α promoter 
using the gold-standard method of bisulfite sequencing. More than a two fold increase 
in cytosine methylation was revealed in Type 2 diabetic patients compared to NGT 
subjects. Additionally, PGC1α promoter methylation in skeletal muscle from impaired 
glucose tolerant (IGT) subjects was similar to that observed in Type 2 diabetic patients. 
This finding suggested that the methylation changes might occur at an early stage in the 
pathogenesis of Type 2 diabetes. Interestingly, methylation levels of the alternative 
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promoter of human PGC1α, DHX15 and GBA3 (two genes proximal to PGC1α) were 
similar in NGT and Type 2 diabetic subjects, which indicated that the observed 
cytosine methylation change of PGC1α was specifically located in the core promoter 
region rather than a broader portion of the chromatin.  
 
Most of the methylated cytosines of PGC-1α promoter were found in non-CpG 
contexts (as described in Paper I). Similarly, incomplete bisulfite conversion could be 
excluded using an unmethylated control generated by PCR. The background level of 
incomplete conversion was much lower than the levels of methylated cytosines 
detected in the experimental samples. An adapted LUMA approach based on restriction 
enzymes (Psp6I and AjnI) digestion and the pyrosequencing technique, rather than 
bisulfite conversion, provided further evidence that non-CpG methylation was present 
at measurable levels in human skeletal muscle. We retrieved numerous genes 
differentially methylated in Type 2 diabetic patients from MeDIP array. The antibody 
used for MeDIP recognizes and binds to 5-methylcytosine in both CpG and non-CpG 
contexts. Thus, non-CpG methylation should be considered when interpreting MeDIP 
results.  
 
2.3.2.2 PGC1α methylation regulates PGC1α mRNA expression 
 
In parallel with the increase in PGC1α promoter methylation level in Type 2 diabetic 
patients, mRNA expression of PGC1α was downregulated by 38%, and negatively 
correlated with promoter methylation. Introducing a methyl group to a single cytosine 
residue of the PGC1α promoter in vitro induced a marked suppression of gene activity 
using a gene reporter assay. Collectively, our results provide direct evidence that the 
methylation status of the PGC1α promoter can regulate mRNA expression.  
 
Reduced mRNA expression of PGC-1α in skeletal muscle obtained from Type 2 
diabetic patients is consistent with previous reports (Mootha et al., 2003; Patti et al., 
2003). PGC1α is involved in stimulation of mitochondrial biogenesis and respiration in 
muscle cells (Wu et al., 1999b). We also found that mitochondrial number was reduced 
and mitochondrial morphology was altered in Type 2 diabetic patients as compared to 
NGT subjects assessed by ultrastructural analysis of skeletal muscle. Additionally, 
several proteins of mitochondrial respiration chain (SUO/complex II, core I/complex III, 
and cytochrome C/CytC), as well as TFAM, a key regulator of mitochondrial DNA 
copy number, were significantly decreased in Type 2 diabetic patients measured by 
western blot analysis.  
 
A large body of evidence indicates that mitochondrial dysfunction is associated with 
skeletal muscle insulin resistance in Type 2 diabetes (Holland et al., 2007; Morino et al., 
2006; Ruderman et al., 1999; Yu et al., 2002). Our data provides evidence for a 
relationship between PGC1α methylation status and mitochondrial function, which 
may further influence insulin sensitivity in Type 2 diabetes, since the magnitude of 
reduction in mtDNA was negatively correlated with quantitative methylation level of 
PGC1α promoter. Thus, PGC1α promoter hypermethylation may contribute to an 
impaired oxidative capacity in skeletal muscle and systemic insulin resistance through 
influencing gene expression. Furthermore, our MeDIP array results revealed 44 
promoter regions related to mitochondrial function were differentially methylated in 
Type 2 diabetes compared to NGT subjects. Thus DNA methylation may play an 
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important role in mitochondrial function by controlling expression of genes involved in 
mitochondrial structure and function. 
 
2.3.2.3 Free fatty acids and TNFα induces hypermethylation of PGC1α 
 
Nutritional factors are related to insulin resistance based on the findings that the 
accumulation of intracellular lipid metabolites from incomplete lipid oxidation due to 
fat overload could inhibit insulin signal transduction to glucose transport (Kim et al., 
2000; Petersen et al., 2004; Ritov et al., 2005). Epigenetic modifications act as 
information superimposed on genetics link environmental factors and gene expression. 
To examine if extracellular factors could alter DNA methylation status of PGC1α, we 
exposed primary human skeletal muscle cells to elevated concentrations of four 
different factors known to induce insulin resistance for 48 hours: glucose, insulin, free 
fatty acids or the inflammatory factor TNF-α. Free fatty acids and TNF-α, but not 
insulin or glucose dramatically triggered hypermethylation of the PGC1α promoter 
[Figure 18]. The observed methylation level was similar after exposure to palmitate or 
oleate, suggesting the methylation process is unlikely to distinguish between a saturated 
fat and an unsaturated fat. Fat overload and inflammation are two competing theories to 
explain insulin resistance in skeletal muscle. The underlying mechanism is 
incompletely understood. Our findings suggest elevated free fatty acids and 
inflammatory factors may induce insulin resistance through epigenetic mechanisms. 
Future effort is warranted to elucidate the potential ‘rate-limiting’ metabolites in 
triggering DNA methylation in response to changes in lipid overload or inflammatory 
factors.  
 
 
 
Figure 18 Free fatty acids induce PGC1α promoter hypermethylation in cultured human myotubes (Paper II 
Figure 5). 
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2.3.2.4 DNMT3B is involved in palmitate-triggered PGC1α hypermethylation 
 
Three functional isoforms of DNA methyltransferase (DNMT), DNMT1, DNMT3A, 
DNMT3B have been identified in mammals (Xie et al., 1999; Yen et al., 1992). The 
process of DNA methylation is based on an enzymatic reaction forming a transient 
covalent complex between DNMTs and targeted cytosine (Santi et al., 1983). To 
dissect whether DNMTs are involved in free fatty acid-induced hypermethylation of the 
PGC1α promoter, we selectively silenced different DNMT isoforms in palmitate-
treated cultured human skeletal muscle cells using siRNA. We transfected a scrambled 
siRNA as a negative control, which is a scrambled sequence of the siRNA target 
sequence to identify any changes of gene expression due to siRNA delivery method or 
siRNA against specific DNMT isoforms. Palmitate treatment increased methylation 
level of the PGC1α promoter and decreased mitochondrial content as measured by the 
ratio mitochondria DNA per nucleus DNA (mtDNA/nDNA). mRNA expression levels 
of several genes related to mitochondrial function and biogenesis were downregulated 
upon palmitate treatment. Silencing of DNMT3B by 43% prevented palmitate-induced 
hypermethylation of PGC1α and defects of mtDNA content, as well as expression of 
genes involved in mitochondrial function [Figure 19]. Silencing of DNMT1 or 
DNMT3A failed to achieve the same effect as silencing of DNMT3B. Based on these 
observations, we conclude DNMT3B is essential to induce hypermethylation of PGC1α 
promoter in response to palmitate stimuli. However, protein content of DNMT3B was 
unaltered in this process. Maintaining and modifying the specific DNA methylation 
pattern is not only related to DNMTs protein amount, but also depends on multiple 
factors including interactions between different methyltransferases, nuclear factors and 
chromatin structure, as well as methyl donors. 
 
 
 
Figure 19 A model to illustrate the potential role of DNMT3B in inducing hypermethylation of the PGC1α 
promoter, which would further influence PGC1α mRNA expression and mitochondrial biogenesis. 
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DNA methylation has been considered to be established early in embryonic stage and 
remains dynamic only during cell division and differentiation. Here we observed that 
changes in DNA methylation levels were associated with alterations in the expression 
of genes involved in mitochondrial function in skeletal muscles obtained from Type 2 
diabetic patients. Rapid DNA methylation changes after exposure to free fatty acids or 
TNFα in terminally differentiated primary human myotubes imply that epigenetic 
marks remain dynamic in somatic cells. These results provide evidence that DNA 
methylation may play an important role to regulate insulin sensitivity in metabolic 
disease states, indicating a strong link between gene and environment. 
 
 
2.3.3 Paper III 
 
Weight loss after gastric bypass surgery induces epigenetic modifications in 
human obesity 
 
A collision of genetic and environmental factors has led to a rapid growth of obesity. 
Conventional strategies for the management of obesity, including lifestyle 
modifications of diet and exercise behavior, are often insufficient and pharmacological 
options are limited (Matthews et al., 1998; Turner et al., 1999). When diet and drugs no 
longer work, many severely obese individuals opt to undergo gastric bypass surgery as 
a means to reduce daily calorie absorption and lose weight. Several lines of evidence 
suggest that gastric bypass surgery reduces comorbidities and improves clinical 
outcomes associated with obesity (Hammoud et al., 2009; Marsk et al., 2010; Sjostrom 
et al., 2004). 
 
2.3.3.1 Clinical characteristics of the study participants 
 
In Paper III, eight non-diabetic obese women (mean BMI=42.1 kg/m
2
) were studied 
before and after gastric bypass surgery. The homeostatic model assessment (HOMA) 
value indicates insulin resistance and β-cell function defects in the obese participants. 
Laparoscopic Roux-en-Y gastric bypass was performed in this study. Sixteen normal 
weight women who did not undergo gastric bypass surgery were studied as control 
group. The levels of insulin, triglycerides, high density lipoprotein (HDL), non-
esterified fatty acids (NEFA) in the obese women were significantly different compared 
to normal weight subjects. Leptin, interleukin-6 (IL6), hepatocyte growth factor (HGF) 
and C-reactive protein (CRP) were increased with obesity. Dramatic weight loss from 
122.3 kg (mean value) before surgery to 88.1 kg (mean value) occurred from gastric 
bypass surgery. Furthermore, fasting glucose, insulin, lipids levels, inflammatory 
factors were normalized after gastric bypass surgery. 
 
The mechanisms for the normalization of insulin sensitivity and reversal of type 2 
diabetes after gastric bypass surgery are unexplained. Changes in DNA methylation 
may provide a mechanism by which environmental influences are linked to changes in 
gene expression and the control of insulin sensitivity with obesity. In Paper II, 
numerous gene promoters were shown to be differentially methylated in Type 2 
diabetic patients compared to normal glucose tolerant subjects. Moreover, DNA 
methylation, particularly in non-CpG context, was involved in modulating insulin 
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sensitivity and mitochondrial function by influencing PGC1α gene activity (Paper II). 
The aim of Paper III is to determine if DNA methylation is involved in the positive 
effect of gastric bypass surgery on human obesity. 
 
2.3.3.2 The transcription of metabolic genes and DNA methylation pattern 
 
To elucidate the potential role of epigenetic modifications in the regulation of gene 
expression in human obesity, as well as gastric bypass surgery-induced weight loss, we 
first examined altered expression of obesity related genes using genome-wide 
microarray approach. We identified 78 genes that were differentially expressed in 
skeletal muscle of obese women compared to normal weight women. These genes were 
classified in lipid metabolic process and mitochondrion. Furthermore, weight loss 
surgery normalized gene expression to similar levels as observed in normal weight 
women. 
 
We determined the role of DNA methylation of specific promoters in regulating gene 
expression in obese women. We applied MBD-affinity methylated DNA enrichment 
protocol to investigate the methylation level of selective 16 genes promoters. Among 
16 promoters studied, the methylation level of 8 promoters was negatively correlated 
with the gene expression, whereas the methylation level of 5 promoters showed a 
positive association. DNA methylation modulates transcription mainly through 
regulating the accessibility of transcriptional factors to the DNA template. Our data 
demonstrates three different transcriptional responses to increases in DNA methylation 
(Negative 8/16, Positive 5/16 and None 3/16). Thus, DNA methylation is not the only 
mechanism influencing gene expression. The consequence of DNA methylation 
regulation appears to be versatile, depending on the different contexts.  
 
We also measured the global DNA methylation levels in skeletal muscle both in CpG 
(CCGG sequence) and non-CpG (CCA/TGG sequence) contexts using the LUMA 
technique. Consistent with our previous finding in Paper II, we detected similar levels 
of non-CpG methylation between lean and obese women. Global methylation was 
unaltered by either obesity or surgery-induced weight loss. Thus, the reported 
differential methylation level of specific promoters does not appear to reflect a global 
level change. 
 
Fat contamination is a major concern in studies of skeletal muscle biopsies from 
obesity subjects. To exclude the possibility of fat difference in vastus lateralis skeletal 
muscle biopsies before and after the surgery, we measured mRNA expression of 
adipsin, an adipose tissue-enriched marker. mRNA expression of adipsin was similar in 
obese  woman before versus after weight loss surgery. Thus, fat contamination in the 
muscle biopsies is unlikely to account for the changes in DNA methylation observed 
after weight loss. 
 
2.3.3.3 PGC1α and PDK4 methylation is altered with obesity and weight loss 
 
PGC1α and PDK4 play an important role in the regulation of efficient energy 
utilization. Both PGC1α and PDK4 were among the 78 genes that were differentially 
expressed in obese women compared to normal weight subjects. We report that the 
decrease in PGC1α mRNA expression and the increase in PDK4 mRNA expression in 
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obesity was normalized by weight loss surgery. We then examined the methylation 
status of these two gene promoters. mRNA expression was inversely correlated with 
the methylation status of the promoters. We observed hypermethylation of PGC1α and 
hypomethylation of PDK4 in obese women in skeletal muscle. Interestingly, the 
methylation pattern after weight loss was normalized to the levels of normal weight 
subjects. 
 
Consistent with our previous finding (Paper I and Paper II), the majority of DNA 
methylation we observed in skeletal muscle from obese women was in non-CpG 
context. To further determine the regulating role of non-CpG methylation in gene 
expression, we performed luciferase activity assay of PDK4 promoter with a 
methylation site introduced in CpC context. Luciferase activity was decreased 19% by 
introducing the single non-CpG methylation site. Combined with our observation in 
Paper II showing a single CpG methylation site in the promoter region could lead to a 
marked suppression of PGC1α luciferase activity, we provide a direct evidence 
methylation is acting as a causative role in regulating gene expression. 
 
Environmental and nutritional factors influence the DNA methylation pattern in 
skeletal muscle. In Paper II, we demonstrated that exposure to free fatty acids or the 
inflammatory factor TNFα could induce hypermethylation of the PGC1α promoter. 
Obesity is characterized by excess accumulation of white adipose tissue due to the 
imbalance between energy intake and expenditure (Rosen and Spiegelman, 2006). The 
elevated triglyceride and free fatty acid levels in obese participants were normalized 
after weight loss induced by gastric bypass surgery. Furthermore, triglyceride levels 
were found to be positively correlated with PGC1α promoter methylation levels, which 
provide further evidence that lipid profiles could trigger dynamic methylation changes 
of the PGC1α promoter in skeletal muscle.  
 
Circulating cytokines and inflammatory factors were also found to be altered in obesity, 
and improved by weight loss surgery. PGC1α methylation levels were positively 
correlated with CRP levels and leptin levels, whereas PDK4 methylation levels were 
negatively correlated with these clinical characteristics. Thus, methylation pattern 
might be affected by systemic factors. 
 
DNA methylation can be modulated by diet supplementation with methyl donors or 
mono carbon metabolites, such as folic acid and homocysteine (Cooney et al., 2002; 
Waterland et al., 2006; Weaver et al., 2005). Restricted food intake and malabsorption 
after gastric bypass surgery could induce folic acid and homocysteine deficiency. 
Furthermore, patients after gastric bypass surgery are prescribed folic acid 
supplementations routinely (5 mg per day). Folic acid and homocysteine measured 
were unaltered in our participants before and after surgery, thereby excluding this 
possibility and further supporting the notion that the observed DNA methylation 
changes are not due to changes of methyl donors. 
 
Metabolic flexibility is used to describe the ability of skeletal muscle to switch between 
utilization of either carbohydrate or fatty acids. However, the ability of skeletal muscle 
from obese individuals to switch between fat and glucose oxidation is impaired (Kelley 
and Mandarino, 2000). Dynamic changes of DNA methylation might contribute to 
metabolic flexibility in skeletal muscle by sensing the environmental and nutritional 
status and modulating gene expression involved in energy homeostasis. 
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The response of DNA methylation change to weight loss was characterized in whole 
blood to determine whether there are tissue-specific changes in DNA methylation with 
obesity or weight loss. Global hypermethylation in peripheral blood leucocytes is 
correlated with systemic inflammation and increased mortality in patients suffered from 
chronic kidney disease (Stenvinkel et al., 2007). We observed that DNA methylation 
level of PGC1α in whole blood coincided with the level in the skeletal muscle (Paper 
III). This result provides evidence to suggest that the DNA methylation pattern in 
blood may mirror the methylation level in muscle for PGC1α. However, we did not 
observe a similar level of methylation of the PDK4 promoter between skeletal muscle 
and whole blood. In our study, we analyzed genomic DNA extracted from the whole 
blood cells. Given that mature human red blood cells and platelets do not have a 
nucleus containing DNA, the DNA from white blood cells contributes the majority of 
the whole blood DNA. Future studies to isolate the different types of white blood cells 
and study the cell type specific methylation pattern in blood are warranted. Moreover, 
additional studies are required to elucidate the methylation pattern in various tissues 
and cell types. Methylation information in blood may serve as a new biomarker in 
human diseases.  
 
In Paper III we demonstrate that obesity and weight loss have a dynamic effect on the 
level of DNA methylation at non-CpG sites in the promoter regions of key genes 
involved in lipid and glucose oxidation in skeletal muscle. Changes in DNA 
methylation may be an early event in reprogramming the metabolic profile of human 
somatic tissues.  
 
Key findings: 
 
Collectively, our findings provide evidence that global DNA methylation levels are 
unaltered either by Type 2 diabetes or obesity in human skeletal muscle biopsies. 
However, DNA methylation alterations were found in specific promoters in Type 2 
diabetes (based on MeDIP array data presented in Paper II (Supplemental Table 2)) 
and obesity (Paper III). We focused on the genes involved in mitochondrial function. 
Specifically, we studied the PGC1α promoter methylation patterns in both Paper II 
and Paper III. To compare the data generated in different cohorts, we here normalized 
PGC1α promoter methylation levels by the levels of NGT controls used in each study 
[Figure 20]. The changes in PGC1α promoter methylation in vastus lateralis skeletal 
muscle observed in IGT, T2D and obese subjects were similar. Moreover, PDK4 
promoter methylation levels were also altered in Type 2 diabetic patients (Kulkarni et 
al., 2011) and obese subjects (Paper III).  
 
Overall, our results provide evidence that the PGC1α and PDK4 promoter methylation 
levels are associated with insulin resistance states. The methylation changes in IGT and 
obese subjects suggest DNA methylation may be an early event in the pathogenesis of 
insulin resistance associated with Type 2 diabetes. The ‘memory’ of insulin resistance 
can be erased by reversing the insulin resistance (e.g. weight loss induced by gastric 
bypass surgery). Luciferase reporter assay results show that a single methylated 
cytosine in the promoter could reduce gene expression (PGC1α in Paper II and PDK4 
in Paper III), which provides direct evidence that methylation may play a causative 
role in regulating gene expression.  
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Figure 20 PGC1α promoter methylation levels in different insulin resistance states (Data are normalized to 
levels measured in NGT subjects for each paper). 
 
It worth noting that there is also a sex difference between cohorts used in Paper II and 
Paper III. Male subjects were studied in Paper II and female subjects in Paper III. 
Sex affects the risk for metabolic syndrome (Glumer et al., 2003; Hu et al., 2004) and 
diabetes (Glumer et al., 2003; Legato et al., 2006). We did not address sex-dependent 
influences on DNA methylation in this thesis. Future work is needed to answer this 
question. 
 
DNA methylation can be triggered by environmental and nutritional factors. Rapid 
changes in DNA methylation were found in differentiated primary human myotubes 
after exposure to free fatty acids or TNFα (Paper II). The underlying mechanism to 
explain the dynamic changes in human tissues is still obscure. We have shown 
DNMT3B is involved in the palmitate-induced hypermethylation of PGC1α promoter 
(Paper II). Further evidence is needed to understand the crosstalk between different 
environmental factors and DNMTs. Additionally, weight loss induced by the surgery 
can restore the methylation of PGC1α promoter (Paper III), which implies 
demethylation mechanisms may be involved. Further investigation of unknown 
mechanism controlling demethylation is needed. 
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3 SUMMARY 
 
Type 2 diabetes and obesity are multifactorial diseases involving interactions between 
genetic and environmental influences. Epigenetics links environmental influences to 
gene expression regulation. Studies presented in this thesis focus on the role of DNA 
methylation and they have expanded the understanding of the regulation of key genes 
involved in maintaining metabolic homeostasis. 
 
 In Paper I, our data demonstrate non-CpG methylation contributes to the total 
DNA methylation in mammals and can be measured at substantial levels. We 
report a bisulfite sequencing bias, which appears to partially explain an 
underestimation of non-CpG methylation levels in mammals. 
 
 In Paper II, using whole genome promoter methylation analysis of skeletal 
muscle from normal glucose tolerant and Type 2 diabetic subjects, 44 
promoters of genes were found to be related to mitochondrial structure and 
function. We identified cytosine hypermethylation of PGC-1α in Type 2 
diabetic subjects and the majority cytosine methylation was in non-CpG 
context. Free fatty acids or TNFα could trigger hypermethylation in cultured 
human myotubes. Selective silencing of the DNMT3B, but not DNMT1 or 
DNMT3A, prevented palmitate-induced non-CpG methylation of PGC-1α. 
 
 In Paper III, global cytosine methylation was unaltered by obesity or gastric 
bypass surgery. Bisulfite sequencing revealed promoter-specific DNA 
methylation changes of PGC-1α and PDK4 with obesity. We also report mRNA 
expression was inversely correlated with promoter methylation level of each 
respective gene. Weight loss restored promoter methylation and mRNA 
expression of PGC-1α and PDK4 to levels comparable with those of non-obese 
women.  
 
Collectively, we identify the existence of non-CpG methylation in mammals and 
describe its functional role in regulating genes associated with insulin resistance in 
Type 2 diabetes and obesity. We also provide evidence that DNA methylation could be 
dynamically remodeled, concomitant with alterations in insulin sensitivity. 
Furthermore, environmental factors such as free fatty acids or TNFα trigger DNA 
methylation changes. Taken together, these studies provide evidence that changes in 
DNA methylation may contribute to the regulation of insulin sensitivity in Type 2 
diabetes and obesity [Figure 21]. 
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Figure 21 DNA methylation contributes to the regulation of insulin sensitivity by modulating mRNA 
expression of genes involved in glucose and lipid metabolism. 
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4 CONCLUSION 
 
Environmental and nutritional factors have a dynamic effect on the level of DNA 
methylation in the promoter regions of key genes involved in lipid and glucose 
oxidation. The studies presented in this thesis have additional implications toward 
clarifying the role of the environmental factors on insulin sensitivity through DNA 
methylation. Changes in DNA methylation may be an early event in reprogramming 
the metabolic profile in human somatic tissues. 
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5 FUTURE PERSPECTIVES 
 
5.1 Tissue-specific DNA methylation 
 
This thesis was mainly focused on DNA methylation in skeletal muscle since this tissue 
is a major site for insulin-mediated glucose disposal (DeFronzo et al., 1985). Defects in 
skeletal muscle lead to the development of whole-body insulin resistance. However, 
Type 2 diabetes is a chronic disorder characterized by impaired insulin secretion of the 
β-pancreatic cells and insulin resistance in skeletal muscle, but also in adipose tissue 
and liver. Several lines of evidence support the role of DNA methylation in metabolic 
disease in individual tissues (Ling et al., 2008; Ling et al., 2007; Ronn et al., 2008). The 
rapid growth in sequencing technology provides an opportunity to investigate the 
epigenome of different tissues, and even the overall epigenetic state of a single cell type. 
Such knowledge will expand our understanding of responses to environmental stimuli 
in different tissues and the crosstalk between multiple organs. Tissue-specific 
methylation patterns may account for susceptibilities and pathogenesis of metabolic 
disease. 
   
5.2 Other epigenetic mechanisms 
 
DNA methylation and histone modifications are two major epigenetic changes. The 
studies in this thesis mainly focused on the potential role of DNA methylation in 
metabolic disease. MicroRNAs (miRNA) are small RNA molecules which could 
negatively regulate gene expression at posttranscriptional levels. miRNA is also 
considered to be within epigenetic arena. There are also interactions and influences 
between different epigenetic modifications (Hou et al., 2008; Lindahl Allen et al., 
2009), e.g. DNA methylation affects histone acetylation and histone methylation (Klose 
and Bird, 2006); miRNA expression can be controlled by epigenetic mechanisms and 
epigenetic machinery can also be affected by miRNA vice versa (Chatterton et al., 2010; 
Chellappan et al., 2010). Future work is needed to elucidate how the other epigenetic 
mechanisms behave or interact with DNA methylation to modulate gene expression in 
human diseases. 
 
5.3 Refining definition of ‘epigenetics’ 
 
Term ‘Epigenetics’ was first coined by the developmental biologist and evolutionist 
Conrad H. Waddington (1905-1975) aiming to emphasize the mechanism driving the 
genotype to the phenotype during development. The definition has been changed and 
refined from time to time. The commonly accepted definition was described by Arthur 
Rigs and colleagues, ‘the study of mitotically and/or meiotically heritable changes in 
gene function that cannot be explained by changes in DNA sequence’. The major 
constraint of this definition is the requirement of ‘heritability’. Are all epigenetic marks 
transmissible during mitosis or meiosis? The reason for questioning this is that many 
chromatin marks are transient. Phosphorylation of the variant histone H2AX after the 
double strand break (Rogakou et al., 1999) would be too transient to be considered a 
heritable epigenetic mark according to the definition described by Arthur Rigs and 
colleagues. In Paper III, we also observed DNA methylation could be altered in 
obesity and this ‘memory of obesity’ could be dynamically erased after weight loss 
induced by gastric bypass surgery.  
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The new definition of epigenetics has been suggested to include the biology of 
chromatin, the various chromatin marks, the RNA interference effects, as well as the 
higher-order structure of chromosomes and the nucleus (Bird, 2007). A unifying 
definition is emerging, ‘the structural adaption of chromosomal regions so as to 
register, signal or perpetuate altered activity states’. The definitions of epigenetics may 
keep changing as long as we gain more knowledge of the epigenetic systems. 
 
5.4 Linking in utero environmental stimuli to adult metabolic disease 
 
Two decades ago, Dr. David Barker first showed that environmental events and 
nutritional conditions in utero could have a lasting impact on adult disease later (Barker 
et al., 1989). This was one of the first clues into why the in utero environment is 
important. The concept of ‘DOHaD’ (Developmental Origins of Health and Disease) is 
now widely accepted and it brings new insights into the pathogenesis and progression 
of human diseases. Fetal growth retardation and low birth weight increases the risk of 
coronary heart disease, Type 2 diabetes and hypertension. These metabolic diseases 
may originate from the poor nutritional environment in utero according to the ‘Barker 
hypothesis’. The study of Dutch famine (1944-1945) also provides a link between 
maternal nutritional status and diseases in the offspring (Painter et al., 2005). 
Additionally, the timing of undernutrition exposure in utero appears to determine which 
organs are affected (Painter et al., 2005). The underlying mechanism is still obscure. 
Epigenetic mechanisms may provide an explanation for these phenomena. Studies on 
epigenetic modifications contribute to our understanding of long-term effects of in 
utero exposure (Breton et al., 2009; Simmons, 2009; Thompson et al., 2010). 
 
DNA methylation appears to fine-tune cell programming, sensing environmental 
changes, marking the chromosome status, regulating gene expression and making the 
body ready to respond to outside. Aberrant DNA methylation is linked to pathogenesis 
of human diseases. In the future, DNA methylation may serve as a diagnostic approach 
to identify persons at risk for metabolic disease. Further studies to modify epigenetic 
influences may inform drug discoveries and treatment strategies for human diseases.  
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